Document is current

Article History

Accepted: 10 January 2025

First Online: 17 February 2025

Competing interests

: C.N.B. has consulted for Abbvie Canada, Amgen Canada, Bristol Myers Squibb Canada, Eli Lilly, Janssen Canada, Pfizer Canada, Ferring Canada, Pendopharm Canada, Sandoz Canada and Takeda Canada. He has received unrestricted educational grants from Abbvie Canada, Boston Scientific, Fresenius-Kabi Canada, Bristol Myers Squibb Canada, Janssen Canada, Pfizer Canada, Organon Canada and Takeda Canada and research grants from Abbvie, Janssen, Bristol Myers Squibb, Pfizer, Sandoz and Takeda. He has been on speaker’s bureaus of Abbvie Canada, Eli Lilly, Fresenius-Kabi, Takeda Canada, Pfizer Canada and Janssen Canada. J.-E.G. has served as a member of the scientific medical advisory committee for Crohn’s and Colitis Canada and as a member and chair of the research advisory committee for Research Manitoba. The other authors declare no competing interests.